查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1324296

到 2030 年病毒疫苗市場預測 - 按類型、型態、容器形狀、生物安全級別類型、技術、疾病、給藥年齡、給藥途徑、最終用戶和地區進行的全球分析

Viral Vaccines Market Forecasts to 2030 - Global Analysis By Type, Form, Container Format, Biosafety Level Type, Technology, Disease, Age of Administration, Route of Administration, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 175+ Pages | 商品交期: 2-3個工作天內

價格

根據Stratistics MRC的數據，2023年全球病毒疫苗市場規模為1005.7億美元，預計到2030年將達到1482.5億美元，預測期內年複合成長率為5.7%。

病毒疫苗被認為是預防病毒病原體引起的病毒感染疾病的最有效手段之一。除了人類免疫缺陷病毒（HIV/AIDS）、埃博拉病毒、流感、COVID-19 和許多其他嚴重的病毒感染疾病之外，病毒還引起許多眾所周知的感染疾病，包括普通感冒、流感和疣。世界範圍內各種病毒感染疾病的流行情況因地區、季節甚至一周中的不同日期而異。因此，對這些藥物的需求也發生了變化。

據世界衛生組織稱，病毒性肝炎罹患3.25 億人，約佔世界人口的 4%，每年導致 134 萬人死亡。

促進因素：感染疾病的蔓延和死灰復燃

生活在人口稠密的地區，旅行更加頻繁，距離更長，人類與野生動物之間的接觸不斷增加，意味著新的感染疾病可以迅速傳播並在世界範圍內引起大流行，引起嚴重關注。此外，出於恐怖主義目的而故意將人、動物或植物引入社區，也可能導致疾病傳播。已發現約 40 種感染疾病，包括 SARS、MERS、埃博拉、基孔肯雅熱、禽流感、豬流感、寨卡病毒和最近的 COVID-19。專家警告說，未來的大流行和流行病將比 COVID-19 致命得多。

疫苗研發成本高

疫苗研發需要大量資金。疫苗需要特殊的設備和監控系統來儲存和運輸，這使得它們比其他藥品更昂貴。儲存和運輸基礎設施不足可能會影響疫苗的功效和品質。從體外研究到商業化，開發過程需要10至15年，成本在8億美元至10億美元之間。此外，疫苗研究的成功率較低，導致公司難以管理營運費用和確保初始投資。因此，疫苗生產和儲存成本高昂，阻礙了市場擴張。

新興市場強勁的成長預測

中國、印度和東南亞等新興地區由於患者人數和可支配收入的增加，疫苗行業具有擴張潛力。大型市場公司被這些新興經濟體的市場開拓潛力所吸引並進行投資。開發負擔得起且易於獲得的免疫接種也是公司投資並重點擴大這些經濟體免疫計劃覆蓋範圍的一個領域。

獲得疫苗的機會不公平

疫苗獲取不公平對病毒疫苗市場構成重大威脅。疫苗的全球分發和供應對於對抗感染疾病和確保公共衛生至關重要。然而，獲得疫苗的機會在不同國家和人群中分佈不均，這阻礙了疫苗接種的有效性，並使某些地區容易爆發疫情。此外，不平等的准入可能由多種要素引起，包括經濟差異、地緣政治課題、供應鏈限制和知識產權。雖然高所得國家往往能夠更好地獲得疫苗，但低收入國家卻難以確保足夠的供應。這種差異不僅導致醫療保健結果的差異，而且破壞了全球控制和消除病毒性疾病的努力。

COVID-19 的影響

由於疫苗接種率和接種疫苗總數下降，COVID-19 大流行影響了世界各地衛生服務的提供，特別是免疫計劃。結果，兒童無法接種疫苗，疫苗市場萎縮。在全球範圍內，各國政府都試圖遏制病毒的傳播，包括大規模封鎖、關閉邊境和禁止大型集會。這些措施推遲了許多舉措的實施，包括疫苗接種活動。此外，為了減少 COVID-19 的影響，世衛組織已發布指導方針，暫停世界各地的大規模免疫規劃活動。

預計小瓶細分市場在預測期內將是最大的細分市場

西林瓶細分市場的需求正在增加，因為它比預充式注射器更具成本效益，並且佔據了市場上最大的佔有率。這些小玻璃或塑膠容器提供無菌環境，以保持疫苗配方的效力和完整性。病毒疫苗市場使用的小瓶的設計符合嚴格的品質標準，確保疫苗的安全性和有效性。然而，這些小瓶是根據其與疫苗成分的相容性、抗破損性以及隨著時間的推移保持產品穩定性的能力而專門選擇的。通常用橡膠塞或鋁蓋密封，以防止污染並保持無菌環境。

在預測期內，凍乾產品領域預計年複合成長率最高

預計冷凍乾燥領域在預測期內的年複合成長率最高。冷凍乾燥通過低溫和減壓下的昇華從疫苗配方中去除水分。因此，凍乾病毒疫苗是固體和乾燥的，在穩定性、儲存和運輸方面具有多種優勢。此外，冷凍乾燥可以通過減少變質和保持效力來幫助延長病毒疫苗的保存期限。通過去除可能引起化學和生物反應的水分，凍乾疫苗更加穩定，可以保存更長時間，無需冷藏。

佔比最大的地區：

據估計，在預測期內，亞太地區將佔據全球病毒疫苗市場的最高佔有率。這是人口膨脹、中產階級可支配收入增加、工業化和都市化快速發展等因素造成的。該地區小型和大型製造商的存在也支持了農用輪胎行業的擴張。斜交農用輪胎採用製造技術和材料生產，能夠以合理的價格提供卓越的負擔能力。天然橡膠是製造斜交輪胎所需的主要原料。因此，亞太地區泰國、印度、越南、印度尼西亞、中國、馬來西亞等國家的天然橡膠供應充足，預計將增加該地區的市場需求。

複合年複合成長率最高的地區：

預計北美地區在預測期內將呈現最高成長率。這一成長歸因於生活水準提高、外國投資和消費增加對農產品的高需求。此外，美國和加拿大等國家的農業成長也導致病毒疫苗的需求增加。與此同時，農業機械化程度也在不斷提高，這也帶動了北美地區的市場成長。

免費客製化服務：

訂閱此報告的客戶將收到以下免費客製化選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（注：基於可行性檢查）
  • 競爭標杆管理
    • 根據產品系列、地域分佈和戰略聯盟對主要企業進行基準測試

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 利益相關者
  • 調查範圍
  • 調查方法
    • 資料挖掘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 假設

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 技術分析
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球病毒疫苗市場：按類型

  • 單價疫苗
  • 多價疫苗

第6章 全球病毒疫苗市場：按型態

  • 液體
  • 冷凍乾燥

第7章 全球病毒疫苗市場：按容器形狀

  • 小瓶
  • 預充式注射器

第8章 全球病毒疫苗市場：按生物安全級別類型

  • 生物安全1級
  • 生物安全2級
  • 生物安全3級
  • 生物安全4級

第9章 全球病毒疫苗市場：按技術分類

  • 不包括 COVID-19感染疾病
    • 結合疫苗
    • 去活化疫苗和亞單位疫苗
    • 減毒活疫苗
    • 重組疫苗
    • 類毒素疫苗
    • 病毒載體疫苗
  • 包括 COVID-19感染疾病
    • 信使核糖核酸 (mRNA) 疫苗
    • 病毒載體疫苗
  • 其他

第10章 全球病毒疫苗市場：按疾病分類

  • 流感
  • 肺炎球菌疾病
  • 聯合疫苗
  • 人類乳突病毒 (HPV)
  • 帶狀皰疹
  • 腦膜炎球菌病
  • 輪狀病毒
  • 麻疹、腮腺炎、德國麻疹(MMR)
  • 水痘
  • 肝炎
  • 白喉、破傷風、百日咳 (DTP)
  • 脊髓灰質炎
  • COVID-19
  • 其他

第11章全球病毒疫苗市場：按給藥年齡分類

  • 兒科疫苗
  • 成人疫苗

第12章全球病毒疫苗市場：按給藥途徑分類

  • 肌內和皮下給藥
  • 口服給藥
  • 其他

第13章全球病毒疫苗市場：按最終用戶分類

  • 地區醫院
  • 醫院
  • 專業中心
  • 診所
  • 其他

第14章全球病毒疫苗市場：按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第15章進展

  • 契約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第16章公司簡介

  • AstraZeneca plc
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novartis, Inc.
  • Novavax, Inc.
  • Pfizer, Inc.
  • Sanofi
  • Seqirus（CSL Limited）
  • Serum institute of India Private Limited
Product Code: SMRC23521

According to Stratistics MRC, the Global Viral Vaccines Market is accounted for $100.57 billion in 2023 and is expected to reach $148.25 billion by 2030 growing at a CAGR of 5.7% during the forecast period. Viral vaccines are considered one of the most effective prevention measures against viral infections caused by viral agents. Along with other serious viral infections including the human immunodeficiency virus (HIV/AIDS), Ebola, influenza, COVID-19, and many others, viruses also cause a number of well-known infectious diseases, including the common cold, flu, and warts. The prevalence of various viral infections varies globally by region, season, and even day of the week. As a result, there is a variable need for these medications.

According to WHO, 325 million people, or roughly 4% of the world's population, live with viral hepatitis and the disease causes 1.34 million deaths per year

Market Dynamics:

Driver:

Infectious diseases are growing more widespread and were re-emerging

Living in more densely populated places, traveling much more frequently and over longer distances than in the past, and increasing human-wildlife contact raise serious concerns about the potential for new infectious diseases to spread quickly and trigger pandemics over the world. Additionally, there's a chance that diseases could spread as a result of intentional introduction into communities of people, animals, or plants for terrorist goals. About 40 infectious diseases, including SARS, MERS, Ebola, chikungunya, avian flu, swine flu, Zika, and most recently COVID-19, have been identified. Future pandemics and epidemics will be much deadlier than COVID-19, experts have warned.

Restraint:

High cost of vaccine development

The process of developing vaccines requires a significant amount of capital. The cost of storing and shipping vaccinations is higher than that of any other pharmaceutical product because they need specific facilities and monitoring systems. The effectiveness and quality of vaccines can suffer from inadequate storage and delivery infrastructure. From in vitro research to marketing, the development process takes 10 to 15 years and costs between US$800 million and US$1 billion. Additionally, because vaccine research has a poor success rate, businesses struggle to control operational expenses and secure initial investments. Therefore, the high cost of vaccine production and storage is limiting market expansion.

Opportunity:

High growth prospects in emerging markets

Due to the rising patient populations and disposable incomes, emerging regions like China, India, and Southeast Asia present expanding potential for the vaccination industry. Major market firms have been enticed to invest in these economies by their development potential. The development of low-cost, accessible vaccinations is another area in which businesses are investing and concentrating in order to expand the reach of immunization programs in these economies.

Threat:

Inequitable access to vaccines

Inequitable access to vaccines poses a significant threat to the viral vaccines market. The global distribution and availability of vaccines are crucial for combating infectious diseases and ensuring public health. However, when access to vaccines is unevenly distributed across countries and populations, it hinders the effectiveness of vaccination efforts and leaves certain regions vulnerable to outbreaks. Additionally, inequitable access can arise from various factors, including economic disparities, geopolitical challenges, supply chain limitations, and intellectual property rights. High-income countries often have better access to vaccines, while lower-income countries struggle to secure an adequate supply. This imbalance not only leads to disparities in healthcare outcomes but also undermines global efforts to control and eradicate viral diseases.

COVID-19 Impact:

The COVID-19 pandemic had an impact on the delivery of health services, particularly immunization programs, all over the world as a fall in vaccination coverage and the overall number of vaccines given was noted. Children missed out on their vaccine doses as a result of this reduction, which reduced the market for these items. Globally, governments made efforts to control the spread by imposing population-wide lockdowns, closing borders, and prohibiting large gatherings. These actions slowed the implementation of numerous initiatives, including vaccine campaigns. Additionally, in order to lessen the effects of COVID-19, the WHO published guidelines for temporarily suspending the activities of mass vaccination programs around the world.

The vials segment is expected to be the largest during the forecast period

The vials segment held the largest share in the market owing to the increasing demand due to its cost effectiveness over prefilled syringes. These small glass or plastic containers provide a sterile environment to preserve the potency and integrity of the vaccine formulations. Vials used in the viral vaccines market are designed to meet stringent quality standards, ensuring the safety and efficacy of the vaccines. However, Vials are specifically chosen for their compatibility with vaccine ingredients, resistance to breakage, and ability to maintain product stability over time. They are typically sealed with rubber stoppers and aluminum caps to prevent contamination and maintain a sterile environment.

The lyophilized segment is expected to have the highest CAGR during the forecast period

During the projection period, the lyophilized segment is expected to have the greatest CAGR. It involves the removal of water from a vaccine formulation through sublimation under low temperature and reduced pressure. The resulting lyophilized viral vaccines are in a solid, dry state, offering several advantages in terms of stability, storage, and transportation. Additionally, lyophilisation helps to extend the shelf life of viral vaccines by reducing degradation and preserving their potency. By removing water, which can contribute to chemical and biological reactions, the lyophilized vaccines exhibit enhanced stability, allowing for longer-term storage without the need for refrigeration.

Region with largest share:

The Asia Pacific region market is estimated to witness the highest share of the global Viral Vaccines market during the forecast period. This is ascribed to elements including the expanding population, rising middle-class discretionary income, and the quick industrialization and urbanization. The expansion of the farm tire sector may also be aided by the region's presence of both small and large-scale manufacturers. Bias farm tires are produced using manufacturing techniques and materials that provide good load capabilities at reasonable prices. Natural rubber is the primary raw material needed to make bias tires. As a result, it is anticipated that the Asia Pacific region's plentiful supply of natural rubber in countries like Thailand, India, Vietnam, Indonesia, China, and Malaysia will increase demand of the market in the region.

Region with highest CAGR:

The North America region is expected to have the highest growth rate over the forecast period. This growth can be attributed high demand for agricultural goods owing to rising living standards, foreign investments and increased consumption. Moreover, growing agricultural industry of countries such as the U.S. and Canada in the region is leading to growing demand for viral vaccines. Along with this, the mechanization in agriculture is also growing in the region, which is also driving the market growth of the North America region.

Key players in the market:

Some of the key players in Viral Vaccines market include: AstraZeneca plc, Emergent BioSolutions Inc., GlaxoSmithKline plc, Merck & Co., Inc., Moderna, Inc., Novartis, Inc., Novavax, Inc., Pfizer, Inc., Sanofi, Seqirus (CSL Limited) and Serum institute of India Private Limited.

Key Developments:

In November 2022, The U.S. FDA granted a Priority Review for GSK's Respiratory Syncytial Virus (RSV) older adult vaccine candidate

In July 2022, CSL SEQIRUS entered into a multi-year influenza research partnership with the University of Liverpool Pandemic Institute to advance influenza protection and pandemic preparedness

In June 2022, Bavarian Nordic A/S entered into a five-year contract with the government of Canada to procure the IMVAMUNE smallpox vaccine

In July 2021, GSK received US FDA approval for Shingrix (Zoster Vaccine Recombinant, Adjuvanted) for the prevention of shingles (herpes zoster) in adults aged 18 years and older who are or will be at increased risk of shingles due to immunodeficiency or immunosuppression caused by known disease or therapy

In June 2021, Merck announced the launch of VAXELIS (Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus b Conjugate and Hepatitis B Vaccine) in the US, developed in partnership with Sanofi Pasteur

Types Covered:

  • Monovalent Vaccines
  • Multivalent Vaccines

Forms Covered:

  • Liquid
  • Lyophilized

Container Formats Covered:

  • Vials
  • Prefilled Syringes

Biosafety Level Types Covered:

  • Biosafety Level 1
  • Biosafety Level 2
  • Biosafety Level 3
  • Biosafety Level 4

Technologies Covered:

  • Excluding COVID 19 Vaccines
  • Including COVID 19 Vaccine
  • Other Technologies

Diseases Covered:

  • Influenza
  • Pneumococcal Diseases
  • Combination Vaccines
  • Human Papillomavirus (HPV)
  • Herpes Zoster
  • Meningococcal Diseases
  • Rotavirus
  • Measles, Mumps, Rubella (MMR)
  • Varicella
  • Hepatitis
  • Diphtheria, Tetanus And Pertussis (DTP)
  • Polio
  • COVID-19
  • Other Diseases

Age of Administrations Covered:

  • Pediatric Vaccine
  • Adult Vaccine

Route of Administrations Covered:

  • Intramuscular & Subcutaneous Administration
  • Oral Administration
  • Other Routes Of Administrations

End Users Covered:

  • Community Hospitals
  • Hospitals
  • Specialty Centres
  • Clinics
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Viral Vaccines Market, By Type

  • 5.1 Introduction
  • 5.2 Monovalent Vaccines
  • 5.3 Multivalent Vaccines

6 Global Viral Vaccines Market, By Form

  • 6.1 Introduction
  • 6.2 Liquid
  • 6.3 Lyophilized

7 Global Viral Vaccines Market, By Container Format

  • 7.1 Introduction
  • 7.2 Vials
  • 7.3 Prefilled Syringes

8 Global Viral Vaccines Market, By Biosafety Level Type

  • 8.1 Introduction
  • 8.2 Biosafety Level 1
  • 8.3 Biosafety Level 2
  • 8.4 Biosafety Level 3
  • 8.5 Biosafety Level 4

9 Global Viral Vaccines Market, By Technology

  • 9.1 Introduction
  • 9.2 Excluding COVID 19 Vaccines
    • 9.2.1 Conjugate Vaccines
    • 9.2.2 Inactivated & Subunit Vaccines
    • 9.2.3 Live Attenuated Vaccines
    • 9.2.4 Recombinant Vaccines
    • 9.2.5 Toxoid Vaccines
    • 9.2.6 Viral vector Vaccines
  • 9.3 Including COVID 19 Vaccine
    • 9.3.1 Messenger Ribonucleic Acid (mRNA) Vaccines
    • 9.3.2 Viral Vector Vaccines
  • 9.4 Other Technologies

10 Global Viral Vaccines Market, By Disease

  • 10.1 Introduction
  • 10.2 Influenza
  • 10.3 Pneumococcal Diseases
  • 10.4 Combination Vaccines
  • 10.5 Human Papillomavirus (HPV)
  • 10.6 Herpes Zoster
  • 10.7 Meningococcal Diseases
  • 10.8 Rotavirus
  • 10.9 Measles, Mumps, Rubella (MMR)
  • 10.10 Varicella
  • 10.11 Hepatitis
  • 10.12 Diphtheria, Tetanus and Pertussis (DTP)
  • 10.13 Polio
  • 10.14 COVID 19
  • 10.15 Other Diseases

11 Global Viral Vaccines Market, By Age of Administration

  • 11.1 Introduction
  • 11.2 Pediatric Vaccine
  • 11.3 Adult Vaccine

12 Global Viral Vaccines Market, By Route of Administration

  • 12.1 Introduction
  • 12.2 Intramuscular & Subcutaneous Administration
  • 12.3 Oral Administration
  • 12.4 Other Routes Of Administrations

13 Global Viral Vaccines Market, By End User

  • 13.1 Introduction
  • 13.2 Community Hospitals
  • 13.3 Hospitals
  • 13.4 Specialty Centres
  • 13.5 Clinics
  • 13.6 Other End Users

14 Global Viral Vaccines Market, By Geography

  • 14.1 Introduction
  • 14.2 North America
    • 14.2.1 US
    • 14.2.2 Canada
    • 14.2.3 Mexico
  • 14.3 Europe
    • 14.3.1 Germany
    • 14.3.2 UK
    • 14.3.3 Italy
    • 14.3.4 France
    • 14.3.5 Spain
    • 14.3.6 Rest of Europe
  • 14.4 Asia Pacific
    • 14.4.1 Japan
    • 14.4.2 China
    • 14.4.3 India
    • 14.4.4 Australia
    • 14.4.5 New Zealand
    • 14.4.6 South Korea
    • 14.4.7 Rest of Asia Pacific
  • 14.5 South America
    • 14.5.1 Argentina
    • 14.5.2 Brazil
    • 14.5.3 Chile
    • 14.5.4 Rest of South America
  • 14.6 Middle East & Africa
    • 14.6.1 Saudi Arabia
    • 14.6.2 UAE
    • 14.6.3 Qatar
    • 14.6.4 South Africa
    • 14.6.5 Rest of Middle East & Africa

15 Key Developments

  • 15.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 15.2 Acquisitions & Mergers
  • 15.3 New Product Launch
  • 15.4 Expansions
  • 15.5 Other Key Strategies

16 Company Profiling

  • 16.1 AstraZeneca plc
  • 16.2 Emergent BioSolutions Inc.
  • 16.3 GlaxoSmithKline plc
  • 16.4 Merck & Co., Inc.
  • 16.5 Moderna, Inc.
  • 16.6 Novartis, Inc.
  • 16.7 Novavax, Inc.
  • 16.8 Pfizer, Inc.
  • 16.9 Sanofi
  • 16.10 Seqirus (CSL Limited)
  • 16.11 Serum institute of India Private Limited

List of Tables

  • Table 1 Global Viral Vaccines Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Viral Vaccines Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Viral Vaccines Market Outlook, By Monovalent Vaccines (2021-2030) ($MN)
  • Table 4 Global Viral Vaccines Market Outlook, By Multivalent Vaccines (2021-2030) ($MN)
  • Table 5 Global Viral Vaccines Market Outlook, By Form (2021-2030) ($MN)
  • Table 6 Global Viral Vaccines Market Outlook, By Liquid (2021-2030) ($MN)
  • Table 7 Global Viral Vaccines Market Outlook, By Lyophilized (2021-2030) ($MN)
  • Table 8 Global Viral Vaccines Market Outlook, By Container Format (2021-2030) ($MN)
  • Table 9 Global Viral Vaccines Market Outlook, By Vials (2021-2030) ($MN)
  • Table 10 Global Viral Vaccines Market Outlook, By Prefilled Syringes (2021-2030) ($MN)
  • Table 11 Global Viral Vaccines Market Outlook, By Biosafety Level Type (2021-2030) ($MN)
  • Table 12 Global Viral Vaccines Market Outlook, By Biosafety Level 1 (2021-2030) ($MN)
  • Table 13 Global Viral Vaccines Market Outlook, By Biosafety Level 2 (2021-2030) ($MN)
  • Table 14 Global Viral Vaccines Market Outlook, By Biosafety Level 3 (2021-2030) ($MN)
  • Table 15 Global Viral Vaccines Market Outlook, By Biosafety Level 4 (2021-2030) ($MN)
  • Table 16 Global Viral Vaccines Market Outlook, By Technology (2021-2030) ($MN)
  • Table 17 Global Viral Vaccines Market Outlook, By Excluding COVID 19 Vaccines (2021-2030) ($MN)
  • Table 18 Global Viral Vaccines Market Outlook, By Conjugate Vaccines (2021-2030) ($MN)
  • Table 19 Global Viral Vaccines Market Outlook, By Inactivated & Subunit Vaccines (2021-2030) ($MN)
  • Table 20 Global Viral Vaccines Market Outlook, By Live Attenuated Vaccines (2021-2030) ($MN)
  • Table 21 Global Viral Vaccines Market Outlook, By Recombinant Vaccines (2021-2030) ($MN)
  • Table 22 Global Viral Vaccines Market Outlook, By Toxoid Vaccines (2021-2030) ($MN)
  • Table 23 Global Viral Vaccines Market Outlook, By Viral vector Vaccines (2021-2030) ($MN)
  • Table 24 Global Viral Vaccines Market Outlook, By Including COVID 19 Vaccine (2021-2030) ($MN)
  • Table 25 Global Viral Vaccines Market Outlook, By Messenger Ribonucleic Acid (mRNA) Vaccines (2021-2030) ($MN)
  • Table 26 Global Viral Vaccines Market Outlook, By Viral Vector Vaccines (2021-2030) ($MN)
  • Table 27 Global Viral Vaccines Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 28 Global Viral Vaccines Market Outlook, By Disease (2021-2030) ($MN)
  • Table 29 Global Viral Vaccines Market Outlook, By Influenza (2021-2030) ($MN)
  • Table 30 Global Viral Vaccines Market Outlook, By Pneumococcal Diseases (2021-2030) ($MN)
  • Table 31 Global Viral Vaccines Market Outlook, By Combination Vaccines (2021-2030) ($MN)
  • Table 32 Global Viral Vaccines Market Outlook, By Human Papillomavirus (HPV) (2021-2030) ($MN)
  • Table 33 Global Viral Vaccines Market Outlook, By Herpes Zoster (2021-2030) ($MN)
  • Table 34 Global Viral Vaccines Market Outlook, By Meningococcal Diseases (2021-2030) ($MN)
  • Table 35 Global Viral Vaccines Market Outlook, By Rotavirus (2021-2030) ($MN)
  • Table 36 Global Viral Vaccines Market Outlook, By Measles, Mumps, Rubella (MMR) (2021-2030) ($MN)
  • Table 37 Global Viral Vaccines Market Outlook, By Varicella (2021-2030) ($MN)
  • Table 38 Global Viral Vaccines Market Outlook, By Hepatitis (2021-2030) ($MN)
  • Table 39 Global Viral Vaccines Market Outlook, By Diphtheria, Tetanus and Pertussis (DTP) (2021-2030) ($MN)
  • Table 40 Global Viral Vaccines Market Outlook, By Polio (2021-2030) ($MN)
  • Table 41 Global Viral Vaccines Market Outlook, By COVID 19 (2021-2030) ($MN)
  • Table 42 Global Viral Vaccines Market Outlook, By Other Diseases (2021-2030) ($MN)
  • Table 43 Global Viral Vaccines Market Outlook, By Age of Administration (2021-2030) ($MN)
  • Table 44 Global Viral Vaccines Market Outlook, By Pediatric Vaccine (2021-2030) ($MN)
  • Table 45 Global Viral Vaccines Market Outlook, By Adult Vaccine (2021-2030) ($MN)
  • Table 46 Global Viral Vaccines Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 47 Global Viral Vaccines Market Outlook, By Intramuscular & Subcutaneous Administration (2021-2030) ($MN)
  • Table 48 Global Viral Vaccines Market Outlook, By Oral Administration (2021-2030) ($MN)
  • Table 49 Global Viral Vaccines Market Outlook, By Other Routes Of Administrations (2021-2030) ($MN)
  • Table 50 Global Viral Vaccines Market Outlook, By End User (2021-2030) ($MN)
  • Table 51 Global Viral Vaccines Market Outlook, By Community Hospitals (2021-2030) ($MN)
  • Table 52 Global Viral Vaccines Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 53 Global Viral Vaccines Market Outlook, By Specialty Centres (2021-2030) ($MN)
  • Table 54 Global Viral Vaccines Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 55 Global Viral Vaccines Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.